Mirikizumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ulcerative Colitis
Conditions
Ulcerative Colitis
Trial Timeline
Dec 9, 2015 → May 7, 2019
NCT ID
NCT02589665About Mirikizumab + Placebo
Mirikizumab + Placebo is a phase 2 stage product being developed by Eli Lilly for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02589665. Target conditions include Ulcerative Colitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03518086 | Phase 3 | Completed |
| NCT03482011 | Phase 3 | Completed |
| NCT02891226 | Phase 2 | Completed |
| NCT02899988 | Phase 2 | Completed |
| NCT02589665 | Phase 2 | Completed |
Competing Products
20 competing products in Ulcerative Colitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirikizumab SC + Mirikizumab IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 2 | 52 |
| Azathioprine + Placebo | Celltrion | Approved | 85 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + Placebo | Astellas Pharma | Phase 3 | 77 |
| Filgotinib Maleate | Eisai | Approved | 85 |
| AJM300 + Placebo | Eisai | Phase 3 | 77 |
| GSK3050002 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + placebo | Eisai | Phase 3 | 77 |
| E6007 + Placebo | Eisai | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 1 | 33 |
| Arm1 + Arm 2 | Zydus Lifesciences | Phase 2 | 52 |
| Mirikizumab + Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| LY3471851 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4268989 + Placebo | Eli Lilly | Phase 2 | 52 |
| Eltrekibart + Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |